New wearable sensor helps patients with bipolar disorder safely monitor lithium levels

NewsGuard 100/100 Score

Patients living with bipolar disorder and depression will soon be able to use a unique wearable sensor to safely monitor their lithium drug levels.

In a study published by the journal ACS Sensors, researchers from the University of Surrey detail how they produced what is believed to be the world's first fiber-based sensors which are ready-to-use to test lithium levels after production. Unlike current sensors on the market that are not wearable, there is no need for pre-conditioning of the sensor in solution for hours beforehand or on a daily-basis.

Lithium is an antipsychotic drug used to treat mood conditions such as bipolar disorder and depression. The drug must be carefully monitored when given to patients, as the wrong dose could prove to be highly toxic. Lithium levels initially need to be checked five to seven days after the first dose, followed by weekly checks until levels stabilize between two doses - after which levels are typically monitored every three months.

The new miniature sensors were shown to quickly and accurately detect lithium concentration levels - from clinically effective, to toxic concentration limits. The sensor is able to detect lithium concentration in the blood even if there is a high concentration of sodium.

Dr Carol Crean, Senior Lecturer in Physical and Material Chemistry at the University of Surrey, said: "We believe that our new sensors will help many people across the world living with mood disorders, such as bipolar and depression. Our sensors will give those who are receiving treatment the opportunity to monitor their lithium levels with a stable and easy to use wearable sensor. They will give people a real alternative to the currently available invasive blood samples, making monitoring their lithium levels as easy as putting on a t-shirt."

According to the Mental Health Foundation, there were four million cases in the UK of mood disorders, including bipolar and depression, and major depression is thought to be the leading cause of disability worldwide.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Antipsychotic use during pregnancy not linked to childhood neurodevelopmental disorders or learning difficulties